PharVision Advisers’s Virco VIRC Stock Holding History

PharVision Advisers’s Portfolio VIRC Stock Details VIRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-33,018	Closed	-$338K	–	526
2024 Q4	$338K	Buy	+33,018	New	+$463K	0.29%	118

Other funds holding VIRC

Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BAM

Bastion Asset Management Montreal, Canada $328M AUM 13.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PharVision Advisers's VIRC Position: Q1 2025 in Review

PharVision Advisers sold out of Virco (VIRC) in Q1 2025, closing a stake of 33,018 shares — an estimated $338K sold.

PharVision Advisers first reported a position in VIRC in Q4 2024 and held it in 1 quarter. The position peaked at $338K in Q4 2024. 89 funds tracked by Wall St. Rank hold VIRC as of Q1 2025.

PharVision Advisers reported no remaining Virco position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 33,018 Virco shares in Q1 2025, an estimated $338K.
PharVision Advisers first reported a position in Virco in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Virco position peaked at $338K in Q4 2024.
89 funds tracked by Wall St. Rank held Virco as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.